1. subject enrolled in a study to investigate a treatment for covid-19 2. require oxygen use, hospitalization or mechanical ventilation 3. tachycardia (hr \> 150 bpm) or hypotension (bp \< 90/60 mmhg) 4. patients who are allergic to the investigational product or similar drugs (or any excipients); 5. subjects with qtcf \> 450 ms 6. subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (bp \> 220/120 mmhg), uncontrolled hypothyroidism (tsh \> 10 iu/l), uncontrolled diabetes mellitus (hba1c \> 12%) 7. alanine transaminase (alt) or aspartate transaminase (ast) \> 5 times the upper limit of normal. 8. estimated glomerular filtration rate (egfr) \< 30 ml/min or requiring dialysis 9. subject (or legally authorized representative) not willing or unable to provide informed consent

1. subject enrolled in a study to investigate a treatment for covid-19 2. require oxygen use, hospitalization or mechanical ventilation 3. tachycardia (hr \> 150 bpm) or hypotension (bp \< 90/60 mmhg) 4. patients who are allergic to the investigational product or similar drugs (or any excipients); 5. subjects with qtcf \> 450 ms 6. subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (bp \> 220/120 mmhg), uncontrolled hypothyroidism (tsh \> 10 iu/l), uncontrolled diabetes mellitus (hba1c \> 12%) 7. alanine transaminase (alt) or aspartate transaminase (ast) \> 5 times the upper limit of normal. 8. estimated glomerular filtration rate (egfr) \< 30 ml/min or requiring dialysis 9. subject (or legally authorized representative) not willing or unable to provide informed consent

subject enrolled in a study to investigate a treatment for covid-19 require oxygen use, hospitalization or mechanical ventilation tachycardia (hr > 150 bpm) or hypotension (bp < 90/60 mmhg) patients who are allergic to the investigational product or similar drugs (or any excipients); subjects with qtcf > 450 ms subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (bp > 220/120 mmhg), uncontrolled hypothyroidism (tsh > 10 iu/l), uncontrolled diabetes mellitus (hba1c > 12%) alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. estimated glomerular filtration rate (egfr) < 30 ml/min or requiring dialysis subject (or legally authorized representative) not willing or unable to provide informed consent

subject enrolled in a study to investigate a treatment for covid-19 require oxygen use, hospitalization or mechanical ventilation tachycardia (hr > 150 bpm) or hypotension (bp < 90/60 mmhg) patients who are allergic to the investigational product or similar drugs (or any excipients); subjects with qtcf > 450 ms subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (bp > 220/120 mmhg), uncontrolled hypothyroidism (tsh > 10 iu/l), uncontrolled diabetes mellitus (hba1c > 12%) alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. estimated glomerular filtration rate (egfr) < 30 ml/min or requiring dialysis subject (or legally authorized representative) not willing or unable to provide informed consent

1. subject enrolled in a study to investigate a treatment for covid-19 2. require oxygen use, hospitalization or mechanical ventilation 3. tachycardia (hr > 150 bpm) or hypotension (bp < 90/60 mmhg) 4. patients who are allergic to the investigational product or similar drugs (or any excipients); 5. subjects with qtcf > 450 ms 6. subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (bp > 220/120 mmhg), uncontrolled hypothyroidism (tsh > 10 iu/l), uncontrolled diabetes mellitus (hba1c > 12%) 7. alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. 8. estimated glomerular filtration rate (egfr) < 30 ml/min or requiring dialysis 9. subject (or legally authorized representative) not willing or unable to provide informed consent

1. subject enrolled in a study to investigate a treatment for covid-19 2. require oxygen use, hospitalization or mechanical ventilation 3. tachycardia (hr > 150 bpm) or hypotension (bp < 90/60 mmhg) 4. patients who are allergic to the investigational product or similar drugs (or any excipients); 5. subjects with qtcf > 450 ms 6. subjects with uncontrolled medical conditions that could compromise participation in the study - uncontrolled hypertension (bp > 220/120 mmhg), uncontrolled hypothyroidism (tsh > 10 iu/l), uncontrolled diabetes mellitus (hba1c > 12%) 7. alanine transaminase (alt) or aspartate transaminase (ast) > 5 times the upper limit of normal. 8. estimated glomerular filtration rate (egfr) < 30 ml/min or requiring dialysis 9. subject (or legally authorized representative) not willing or unable to provide informed consent